Sothema: Cialis Included in the Accounts of the Moroccan Laboratory
The Moroccan pharmaceutical company Sothema has incorporated products from the Cialis brand into its portfolio, following the acquisition of rights related to this treatment from the American group Eli Lilly. This move marks a significant evolution in the group’s development strategy, which continues to strengthen its therapeutic portfolio.
According to the latest financial indicators, this acquisition has had a direct impact on the group’s investments, reflecting a desire to expand its activities towards high-value-added products.
A Move That Strengthens Growth Strategy
This integration is part of Sothema’s overall growth trajectory, as the company has multiplied strategic operations in recent years, particularly in the fields of cardiology, oncology, and specialized therapeutic solutions.
The group continues its diversification policy, consolidating its presence in pharmaceutical segments characterized by high demand both in Morocco and internationally.
A Rapidly Expanding Pharmaceutical Market
The Moroccan pharmaceutical industry continues to show sustained growth, driven by increased demand for medications and the innovative efforts of local players.
Sothema, one of the sector’s leaders, is benefiting from this momentum and is progressively reinforcing its positioning through international partnerships and targeted acquisitions.
A Value-Added Strategy
The integration of Cialis into the group’s portfolio aligns with a strategy aimed at optimizing revenue and enhancing the quality of offered products.
Such operations enable Sothema to solidify its profitability while strengthening its presence in economically promising therapeutic segments.
Consolidating Sothema’s Leadership
With this new step, Sothema reaffirms its growth strategy based on innovation, acquisitions, and the expansion of its drug portfolio.
The group continues to establish itself as a leading player in the pharmaceutical industry in Morocco and across the African continent.
